Your Search Results

Optimal use of dedicated device for calcified lesions

20 May 2026 – From EuroPCR 2026

This session delves into the optimal utilization of dedicated devices for managing complex coronary calcification. Explore decision-making strategies involving orbital atherectomy and cutting balloon techniques, as well as advanced approaches like contact intravascular lithotripsy for stented calcified nodules. Additional focus is given to ablative and modifying...

PFO closure - Progression in practice

20 May 2026 – From EuroPCR 2026

This session presents progressive insights into patent foramen ovale (PFO) closure, comparing outcomes across age groups and evaluating residual shunting via transcranial Doppler. It highlights tailored antiplatelet therapy durations from the PROLONG registry, long-term safety and efficacy data, morphological variations of the fossa ovalis, and the...

Stay calm and carry on: bailout techniques for calcified lesions

20 May 2026 – From EuroPCR 2026

Focused on bailout techniques for calcified lesions, this session addresses challenging scenarios such as deformed stents, post-CABG angioplasty complications, and balloon uncrossable lesions in tortuous anatomy. It provides practical approaches to manage complex calcium-related complications that may arise unexpectedly during intervention, ensuring preparedness for difficult procedural...

From entry to exit: managing arterial access for nurses and allied professionals

20 May 2026 – From EuroPCR 2026

This session focuses on arterial access management tailored for nurses and allied health professionals. It highlights key anatomical landmarks, demonstrates the purpose and use of common vascular closure devices through live manikin demonstrations, and discusses the essential role of nursing and allied staff in vascular access...

5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

01 Apr 2025

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.